不同评分系统对失代偿期肝硬化患者短期和中期死亡风险预测能力的比较

凡小丽; 文茂瑶; 沈怡; 杨丽

doi:10.3969/j.issn.1001-5256.2017.07.016

不同评分系统对失代偿期肝硬化患者短期和中期死亡风险预测能力的比较

DOI: 10.3969/j.issn.1001-5256.2017.07.016

四川大学华西医院消化内科

详细信息

中图分类号: R575.2
计量
- 文章访问数: 1664
- HTML全文浏览量: 11
- PDF下载量: 404
- 被引次数: 0
出版历程
- 收稿日期: 2016-12-16
- 出版日期: 2017-07-20

Comparison of the abilities of five scoring systems to predict short-term and medium-term death risks in patients with decompensated cirrhosis

Department of Gastroenterology, West China Hospital, Sichuan University

摘要

摘要: 目的比较Child-Turcotte-Pugh（CTP）评分、MELD评分、MELD-Na评分、iMELD评分以及MESO指数对失代偿期肝硬化患者3、12个月死亡风险的预测价值。方法回顾性分析2014年1月1日-2014年12月31日于四川大学华西医院消化内科住院的269例失代偿期肝硬化患者的资料。计算患者入院48 h以内评估得到的上述评分分值,并对所有患者随访至1年以上。满足正态分布的计量资料组间比较若方差齐性采用t检验;不满足正态分布的计量资料组间比较采用Mann-Whitney U检验。计数资料组间比较采用χ2检验;采用logistic回归分析法进行多因素分析、Hosmer-Lemeshow检验各模型拟合度、Kaplan-Meier生存分析法对生存率进行分析。结果 3个月内死亡患者25例,12个月内死亡患者38例;TBil、肌酐、尿素、Alb、WBC、PT、INR、血钠、入院时是否合并肝性脑病、腹水程度、入院时CTP评分、MELD评分、MELD-Na评分、iMELD评分、MESO评分、既往是否出现肝性脑病、出院后是否对因治疗等因素在12个月内死亡患者与存活患...
- 肝硬化 /
- 预后 /
- 对比研究
Abstract: Objective To compare the abilities of Child-Turcotte-Pugh (CTP) score, Model for End-Stage Liver Disease (MELD) , MELD combined with serum sodium concentration (MELD-Na) , integrated MELD (iMELD) , and MELD to SNa ratio (MESO) to predict short-term and medium-term death risks in patients with decompensated cirrhosis at months 3 and 12.Methods The records of 269 patients with decompensated cirrhosis in Department of Gastroenterology, West China Hospital, Sichuan University from January 1 to December31, 2014 were retrospectively analyzed.The CTP, MELD, MELD-Na, iMELD, and MESO scores were evaluated for these patients within48 hours after admission and these patients were followed up for at least 12 months.The predictive abilities of these five scoring systems were evaluated by the area under the receiver operating characteristic curve (AUC) at months 3 and 12.Comparison of continuous data was conducted using t test (for data with normal distribution and homogeneity of variance) or Mann-Whitney U test (for data with non-normal distribution) , while comparison of categorical data was conducted using χ2 test.Meanwhile, logistic regression analysis, Hosmer-Lemeshow goodness-of-fit test, and Kaplan-Meier survival analysis were performed.Results Twenty-five (9.29%) and thirty-eight (14.13%) of all patients died within 3 months and 12 months, respectively.There were significant differences between the patients who died and survived within 12 months in total bilirubin, creatinine, urea, albumin, white blood cell count, prothrombin time, international normalized ratio, serum sodium, the presence or absence of hepatic encephalopathy on admission, degree of ascites, the CTP, MELD, MELD-Na, iMELD, and MESO scores on admission, history of hepatic encephalopathy, and treatments for these factors after discharge (all P<0.05) .The multivariate logistic regression analysis revealed that all five scores were independent prognostic factors for the patients (odds ratios:CTP=2.020, MELD=1.252, MELD-Na=1.088, iMELD=1.114, MESO=1.368;all P<0.01) .At month 3, CTP score had the highest AUC (0.823) , followed by MESO (0.796) , MELD (0.789) , MELD-Na (0.775) , and iMELD (0.770) scores.At month 12, the AUC values for CTP, MELD, MELD-Na, iMELD, and MESO were 0.834, 0.798, 0777, 0.801, and 0.804, respectively.Therefore, CTP score was best in predicting the death risks within 3 and 12 months.The Kaplan-Meier curves showed that these five scoring methods clearly distinguished 12-month cumulative survival rates for these patients (all P<0.05) .Conclusion CTP score, MELD score, and three MELD-related scores can reliably predict both short-term and medium-term death risks in patients with decompensated cirrhosis.Moreover, CTP score may have a better ability to predict death risks in patients with decompensated cirrhosis in China.
- liver cirrhosis /
- prognosis /
- comparative study

HTML全文

参考文献(31)

[1]GARCIA-TSAO G, ABRALDES JG, BERIGOTTI A, et al.Portal hypertensive bleeding in cirrhosis:risk stratification, diagnosis, and management:2016 practice guidance by the American Association for the study of liver diseases[J].Hepatology, 65 (1) :310-335.

[2]SCHUPPAN D, AFDHAL NH.Liver cirrhosis[J].Lancet, 2008, 371 (9615) :838-851.

[3]D'AMICO G, PASTA L, MORABITO A, et al.Competing risks and prognostic stages of cirrhosis:a 25-year inception cohort study of 494 patients[J].Aliment Pharmacol Ther, 2014, 39 (10) :1180-1193.

[4]INFANTE-REVARD C, ESNAOLA S, VILLENEUVE JP.Clinical and statistical validity of conventional prognostic factors in predicting short-term survival among cirrhotics[J].Hepatology, 1987, 7 (4) :660-664.

[5]HUO TI, LIN HC, LEE SD.Model for end-stage liver disease and organ allocation in liver transplantation:where are we and where should we go?[J].J Chin Med Assoc, 2006, 69 (5) :193-198.

[6] MALINCHOC M, KAMATH PS, GORDON FD, et al.A model to predict poor survival in patients undergoing transjugular intrahepatic portosystemic shunts[J].Hepatology, 2000, 31 (4) :864-871.

[7]FRREEMAN RB.Overview of the MELD/PELD system of liver allocation indications for liver transplantation in the MELD era:evidence-based patient selection[J].Liver Transpl, 2004, 10 (10Suppl 2) :s2-s3.

[8]HUO TI, LEE SD, LIN HC.Selecting an optimal prognostic system for liver cirrhosis:the model for end-stage liver disease and beyond[J].Liver Int, 2008, 28 (5) :606-613.

[9]KIIM WR, BIGGINS SW, KREMERS WK, et al.Hyponatremia and mortality among patients on the liver-transplant waiting list[J].NEngl J Med, 2008, 359 (10) :1018-1026.

[10]CARDENAS A, GINES P.Predicting mortality in cirrhosis-serum sodium helps[J].N Engl J Med, 2008, 359 (10) :1060-1062.

[11]RUF AE, KREMERS WK, CHAVEZ LL, et al.Addition of serum sodium into the MELD score predicts waiting list mortality better than MELD alone[J].Liver Transpl, 2005, 11 (3) :336-343.

[12]BIGGINS SW, KIM WR, TERRAULT NA, et al.Evidence-based incorporation of serum sodium concentration into MELD[J].Gastroenterology, 2006, 130 (6) :1652-1660.

[13]LV XH, LIU HB, WANG Y, et al.Validation of model for end-stage liver disease score to serum sodium ratio index as a prognostic predictor in patients with cirrhosis[J].J Gastroenterol Hepatol, 2009, 24 (9) :1547-1553.

[14]D'AMICO, G, GATCIA-TSAO G, PAGLIARO L.Natural history and prognostic indicators of survival in cirrhosis:a systematic review of 118 studies[J].J Hepatol, 2006, 44 (1) :217-231.

[15]LUCA A, ANGERMAYR B, BERTOLINI G, et al.An integrated MELD model including serum sodium and age improves the prediction of early mortality in patients with cirrhosis[J].Liver Transpl, 2007, 13 (8) :1174-1180.

[16]CHENG XP, ZHAO J, CHEN Y, et al.Comparison of the ability of the PDD-ICG clearance test, CTP, MELD, and MELD-Na to predict short-term and medium-term mortality in patients with decompensated hepatitis B cirrhosis[J].Eur J Gastroenterol Hepatol, 2016, 28 (4) :444-448.

[17]BISELLI M, GITTO S, GRAMENZI A, et al.Six score systems to evaluate candidates with advanced cirrhosis for orthotopic liver transplant:which is the winner?[J].Liver Transpl, 2010, 16 (8) :964-973.

[18]JIANG M, LIU F, XIONG WJ, et al.Comparison of four models for end-stage liver disease in evaluating the prognosis of cirrhosis[J].World J Gastroenterol, 2008, 14 (42) :6546-6550.

[19]HUO TI, Lin HC, HUO SC, et al.Comparison of four model for end-stage liver disease-based prognostic systems for cirrhosis[J].Liver Transpl, 2008, 14 (42) :837-844.

[20]FAN XL, YANG LI.Method to assess the accuracy of scores in mortality prediction:more than receiver operating characteristic curve[J].Eur J Gastroenterol Hepatol, 2016, 28 (7) :850.

[21]HUO TI, WANG YW, YANG YY, et al.Model for end-stage liver disease score to serum sodium ratio index as a prognostic predictor and its correlation with portal pressure in patients with liver cirrhosis[J].Liver Int, 2007, 27 (4) :498-506.

[22]HUO TI, WU JC, LIN HC, et al.Evaluation of the increase in model for end-stage liver disease (Delta MELD) score over time as a prognostic predictor in patients with advanced cirrhosis:risk factor analysis and comparison with initial MELD and Child-TurcottePugh score[J].J Hepatol, 2005, 42 (6) :826-832.

[23]WIESNER R, EDWARDS E, FREEMAN R, et al.Model for end-stage liver disease (MELD) and allocation of donor livers[J].Gastroenterology, 2003, 124 (1) :91-96.

[24]RAHIMI-DEHKORDI N, NOURIJELYANI K, NASIRI-TOUSIM, et al.Model for End stage Liver Disease (MELD) and ChildTurcotte-Pugh (CTP) scores:ability to predict mortality and removal from liver transplantation waiting list due to poor medical conditions[J].Arch Iran Med, 2014, 17 (2) :118-121.

[25]GOTTHARDT D, WEISS KH, BAUMGARTNER M, et al.Limitations of the MELD score in predicting mortality or need for removal from waiting list in patients awaiting liver transplantation[J].BMC Gastroenterol, 2009, 9:72.

[26]LEMESHOW S, HOSMER DW Jr.A review of goodness of fit statistics for use in the development of logistic regression models[J].Am J Epidemiol, 1982, 115 (1) :92-106.

[27]JOHNSON KB, CAMPBELL EJ, CHI H, et al.Advanced disease, diuretic use, and marital status predict hospital admissions in an ambulatory cirrhosis cohort[J].Dig Dis Sci, 2014, 59 (1) :174-182.

[28]LEE YH, HSU CY, HUO TI.Assessing liver dysfunction in cirrhosis:role of the model for end-stage liver disease and its derived systems[J].J Chin Med Assoc, 2013, 76 (8) :419-424.

[29]CHOLONGITAS E, MARELLI L, KERRY A, et al.Different methods of creatinine measurement significantly affect MELD scores[J].Liver Transpl, 2007, 13 (4) :523-529.

[30]TROTTER JF, OLSON J, LEFKOWITZ J, et al.Changes in international normalized ratio (INR) and model for endstage liver disease (MELD) based on selection of clinical laboratory[J].Am JTransplant, 2007, 7 (6) :1624-1628.

[31]CHOLONGTITAS E, MARELLI L, KERRY A, et al.Female liver transplant recipients with the same GFR as male recipients have lower MELD scores-a systematic bias[J].Am J Transplant, 2007, 7 (3) :685-692.

施引文献

资源附件(0)

访问统计